Judith A O'Brien

Summary

Affiliation: Caro Research Institute
Country: USA

Publications

  1. ncbi Direct medical costs of complications resulting from type 2 diabetes in the U.S
    J A O'Brien
    Caro Research, Concord, MA 01742, USA
    Diabetes Care 21:1122-8. 1998
  2. ncbi Utilization of health care services by patients with chronic obstructive pulmonary disease
    J A O'Brien
    Caro Research Institute, Concord, MA 01742, USA
    Respir Med 97:S53-8. 2003
  3. ncbi Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000
    Judith A O'Brien
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Clin Ther 25:1017-38. 2003
  4. ncbi Cost of managing an episode of relapse in multiple sclerosis in the United States
    Judith A O'Brien
    Caro Research Institute, Concord, MA 01742, USA
    BMC Health Serv Res 3:17. 2003
  5. ncbi Hospitalization for pertussis: profiles and case costs by age
    Judith A O'Brien
    Caro Research Institute, 336 Baker Avenue, Concord, MA, USA
    BMC Infect Dis 5:57. 2005
  6. ncbi Managing meningococcal disease in the United States: Hospital case characteristics and costs by age
    Judith A O'Brien
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 9:236-43. 2006
  7. ncbi Direct medical cost of managing deep vein thrombosis according to the occurrence of complications
    Judith A O'Brien
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Pharmacoeconomics 20:603-15. 2002
  8. ncbi Cost of managing complications resulting from type 2 diabetes mellitus in Canada
    Judith A O'Brien
    Caro Research Institute, Concord, MA, USA
    BMC Health Serv Res 3:7. 2003
  9. ncbi Diabetes in Canada: direct medical costs of major macrovascular complications
    J A O'Brien
    Caro Research, 336 Baker Avenue, Concord, MA 01742, USA
    Value Health 4:258-65. 2001
  10. ncbi Alzheimer's disease and other dementia in nursing homes: levels of management and cost
    J A O'Brien
    Caro Research, Concord, Massachusetts 01742, USA
    Int Psychogeriatr 13:347-58. 2001

Detail Information

Publications69

  1. ncbi Direct medical costs of complications resulting from type 2 diabetes in the U.S
    J A O'Brien
    Caro Research, Concord, MA 01742, USA
    Diabetes Care 21:1122-8. 1998
    ..To estimate direct medical costs of managing the complications of type 2 diabetes...
  2. ncbi Utilization of health care services by patients with chronic obstructive pulmonary disease
    J A O'Brien
    Caro Research Institute, Concord, MA 01742, USA
    Respir Med 97:S53-8. 2003
    ....
  3. ncbi Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000
    Judith A O'Brien
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Clin Ther 25:1017-38. 2003
    ..It is not uncommon for people to first realize they have diabetes mellitus due to the appearance of a related complication...
  4. ncbi Cost of managing an episode of relapse in multiple sclerosis in the United States
    Judith A O'Brien
    Caro Research Institute, Concord, MA 01742, USA
    BMC Health Serv Res 3:17. 2003
    ..The purpose of this study was to determine the direct medical US cost of managing multiple sclerosis relapses...
  5. ncbi Hospitalization for pertussis: profiles and case costs by age
    Judith A O'Brien
    Caro Research Institute, 336 Baker Avenue, Concord, MA, USA
    BMC Infect Dis 5:57. 2005
    ..It has been reported that from 1997-2000, 20% of all pertussis cases required hospitalization in the US. This analysis examined demographics, case fatality rate, resource use and costs of hospital care related to pertussis by age...
  6. ncbi Managing meningococcal disease in the United States: Hospital case characteristics and costs by age
    Judith A O'Brien
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 9:236-43. 2006
    ..The goal of this analysis was to examine hospitalized cases of meningitis and meningococcemia to identify case characteristics, resource use, and inpatient care costs...
  7. ncbi Direct medical cost of managing deep vein thrombosis according to the occurrence of complications
    Judith A O'Brien
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Pharmacoeconomics 20:603-15. 2002
    ..While efficacy and safety remain the principal basis for choosing a therapy, the economic consequences of that choice should be considered as well...
  8. ncbi Cost of managing complications resulting from type 2 diabetes mellitus in Canada
    Judith A O'Brien
    Caro Research Institute, Concord, MA, USA
    BMC Health Serv Res 3:7. 2003
    ..Data were obtained from many Canadian sources, including the Ontario Case Cost Project, physician and laboratory fee schedules, formularies, reports, and literature. All costs are expressed in 2000 Canadian dollars...
  9. ncbi Diabetes in Canada: direct medical costs of major macrovascular complications
    J A O'Brien
    Caro Research, 336 Baker Avenue, Concord, MA 01742, USA
    Value Health 4:258-65. 2001
    ..To estimate direct medical costs of managing major macrovascular complications in diabetic patients...
  10. ncbi Alzheimer's disease and other dementia in nursing homes: levels of management and cost
    J A O'Brien
    Caro Research, Concord, Massachusetts 01742, USA
    Int Psychogeriatr 13:347-58. 2001
    ..To estimate comparative management levels and the annual cost of caring for a nursing home resident with and without dementia...
  11. ncbi The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences
    Judith A O'Brien
    Caro Research Institute, Concord, MA, 01742, USA
    Infect Control Hosp Epidemiol 28:1219-27. 2007
    ..To estimate the clinical and economic burden of Clostridium difficile-associated disease (CDAD) in Massachusetts over 2 years...
  12. ncbi Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis
    J Jaime Caro
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Pharmacoeconomics 20:593-602. 2002
    ....
  13. ncbi Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 10:13-22. 2007
    ..To conduct a cost-benefit assessment of prevention of sudden cardiac deaths with an implantable cardioverter defibrillator (ICD) versus amiodarone from the perspective of the health-care systems in the UK and France...
  14. ncbi Pertussis immunization of adolescents in the United States: an economic evaluation
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Pediatr Infect Dis J 24:S75-82. 2005
    ..Although there is considerable uncertainty surrounding key inputs, the results indicate that the conditions required for adolescent immunization to be economically warranted are realistic...
  15. ncbi Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences
    Krista F Huybrechts
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 12:16-9. 2009
    ..This intervention was shown to be cost-effective in the United States. This paper presents the Canadian adaptation...
  16. ncbi Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States
    Kristen Migliaccio-Walle
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Clin Ther 25:1806-25. 2003
    ..CONCLUSIONS: These results suggest that use of galantamine in patients with AD in the United States could reduce the use of costly resources such as formal home care and nursing homes, leading to cost savings over time...
  17. ncbi Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Curr Med Res Opin 22:2233-42. 2006
    ..In addition, this model illustrates that discrete event simulation is a useful and versatile tool for budget impact analyses...
  18. ncbi Modeling the efficiency of reaching a target intermediate end point: a case study in type 2 diabetes in the United States
    J Jaime Caro
    Caro Research Institute, Concord, MA, USA
    Value Health 7:13-21. 2004
    ..A case study addresses the economic efficiency of obtaining dual glycemic control over time, according to initial choice of treatment...
  19. ncbi The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada
    J Jaime Caro
    Caro Research Institute, Concord, MA, USA
    BMC Health Serv Res 6:99. 2006
    ..Documentation of the hospitalizations rates following a stroke provides the inputs required for planning health services and to evaluate the economic efficiency of any new therapies...
  20. ncbi Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus
    Alexandra Ward
    Caro Research Institute, 336 Baker Avenue, Concord, MA 01742, USA
    Expert Opin Pharmacother 6:601-8. 2005
    ..However, additional treatment costs of achieving recommended glycaemic control levels are predicted to be at least partially offset in the long term by the reduction of diabetes-related complications and their related management costs...
  21. ncbi Lifetime costs of complications resulting from type 2 diabetes in the U.S
    J Jaime Caro
    Caro Research Institute, Concord, Massachusetts, USA
    Diabetes Care 25:476-81. 2002
    ..To model the lifetime costs associated with complications of type 2 diabetes...
  22. ncbi Costs and medical care consequences associated with the diagnosis of peripheral arterial disease
    Kristen Migliaccio-Walle
    Caro Research Institute, Boston, Massachusetts 01742, USA
    Pharmacoeconomics 23:733-42. 2005
    ..By the end of year 1, this burden is comparable with a diagnosis of MI...
  23. ncbi Impact of thalassemia major on patients and their families
    J Jaime Caro
    Caro Research Institute, Concord, MA 07142, USA
    Acta Haematol 107:150-7. 2002
    ..To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs, and the patient's physical and social well-being...
  24. ncbi Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France
    Alexandra Ward
    Caro Research Institute, Concord, Massachusetts, USA
    Infect Control Hosp Epidemiol 26:288-92. 2005
    ..Bordetella pertussis is highly contagious, and because immunity wanes after vaccination, it continues to be a cause of cough among adults...
  25. ncbi Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis
    Krista F Huybrechts
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 8:549-61. 2005
    ..Thus, a model of the predicted long-term consequences of sevelamer compared with calcium-based binders (acetate and carbonate) was developed...
  26. ncbi Are hypoglycaemia and other adverse effects similar among sulphonylureas?
    Maribel Salas
    Caro Research Institute, Boston, Massachusetts, USA
    Adverse Drug React Toxicol Rev 21:205-17. 2002
    ..More work in this area is needed to homogenise the definition of hypoglycaemia, to get consensus on the methods for detection and data collection, as well as to further patient and physician education...
  27. ncbi Economic burden of pertussis and the impact of immunization
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Pediatr Infect Dis J 24:S48-54. 2005
    ..Despite the existing gaps in data, further research using the most current data should facilitate decisions on new vaccination strategies by describing conditions for favorable results and quantifying the margin of uncertainty...
  28. ncbi An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use
    Alexandra Ward
    Caro Research Institute, Concord, MA, USA
    BMC Clin Pharmacol 2:3. 2002
    ..The objective of this study was to investigate patients' reasons for missing iron chelation therapy with desferrioxamine, and the support to sustain life-long adherence to treatment...
  29. ncbi Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden
    Frances B Garfield
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Pharmacoeconomics 20:629-37. 2002
    ..Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective in managing patients with Alzheimer's disease in clinical trials...
  30. ncbi Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands
    J Jaime Caro
    Caro Research Institute, Boston, Mass, USA
    Dement Geriatr Cogn Disord 14:84-9. 2002
    ..The economic impact of dementia on the Dutch health and social services is substantial...
  31. ncbi Economic implications of growth hormone use in patients with short bowel syndrome
    Kristen Migliaccio-Walle
    Caro Research Institute, Concord, MA 01742, USA
    Curr Med Res Opin 22:2055-63. 2006
    ..05). This study evaluates the economic impact of somatropin use in the management of short bowel syndrome...
  32. ncbi Modeling the implications of changes in vascular calcification in patients on hemodialysis
    Krista F Huybrechts
    Caro Research Institute, 336 Baker Avenue, Concord, MA 01742, USA
    Kidney Int 67:1532-8. 2005
    ..To understand the implications of this effect for cardiovascular events, risk equations are needed...
  33. ncbi Long term cost-of-illness in stroke: an international review
    Krista A Payne
    Caro Research Institute, Montreal, Quebec, Canada
    Pharmacoeconomics 20:813-25. 2002
    ..Consensus on standard cost variables and methods for projections of resource use and survival over time are clearly warranted...
  34. ncbi Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone
    Alexandra Ward
    Caro Research Institute, Concord, MA 01742, USA
    Curr Med Res Opin 23:2333-45. 2007
    ..This simulation compared managing chronic osteoarthritis pain with once-daily OROS hydromorphone with an equianalgesic dose of extended-release (ER) oxycodone administered two or three times a day...
  35. ncbi Assessment of compliance with osteoporosis treatment and its consequences in a managed care population
    Krista F Huybrechts
    Caro Research Institute, 336 Baker Avenue, Concord, MA 01742, USA
    Bone 38:922-8. 2006
    ..To evaluate non-compliance with osteoporosis medications as well as its implications for health and economic outcomes in actual practice...
  36. ncbi Pharmacoeconomic analyses using discrete event simulation
    J Jaime Caro
    Caro Research Institute, 336 Baker Avenue, Concord, MA 01742, USA
    Pharmacoeconomics 23:323-32. 2005
    ....
  37. ncbi The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis
    J Jaime Caro
    Caro Research Institute, Concord, Mass, USA
    J Clin Psychiatry 63:1135-9. 2002
    ..The relative risk of diabetes among patients undergoing risperidone treatment was compared with that of patients receiving olanzapine...
  38. ncbi Describing cognitive decline of patients at the mild or moderate stages of Alzheimer's disease using the Standardized MMSE
    Alexandra Ward
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Int Psychogeriatr 14:249-58. 2002
    ..To describe the progression of patients with mild or moderate Alzheimer's disease (AD) to a severe stage using the Standardized Mini-Mental State Examination (SMMSE)...
  39. ncbi Pharmacoeconomic evidence and considerations for triptan treatment of migraine
    J Jaime Caro
    Caro Research Institute, 336 Baker Avenue, Concord, MA, USA
    Expert Opin Pharmacother 3:237-48. 2002
    ..Thus far, few analyses have explicitly included quality of life (QOL) in their analyses and pharmacoeconomic analyses comparing the different triptans are scant. More research is required in these areas...
  40. ncbi Economic and health consequences of managing bradycardia with dual-chamber compared to single-chamber ventricular pacemakers in Italy
    Huseyin Baris Deniz
    Caro Research Institute, Concord, Massachusetts 01742, USA
    J Cardiovasc Med (Hagerstown) 9:43-50. 2008
    ..Dual-chamber pacemakers lower the risk of developing atrial fibrillation and pacemaker syndrome...
  41. ncbi Clinical and economic burden of infused iron chelation therapy in the United States
    Krista A Payne
    Caro Research Institute, 185 Dorval Avenue, Montreal, Quebec, Canada
    Transfusion 47:1820-9. 2007
    ..Current ICT requires burdensome 8- to 12-hour infusions five to seven times per week...
  42. ncbi The impact of compliance with osteoporosis therapy on fracture rates in actual practice
    J Jaime Caro
    Caro Research Institute, 336 Baker Avenue, Concord, MA 01742, USA
    Osteoporos Int 15:1003-8. 2004
    ..Noncompliance could considerably limit the effectiveness observed in actual practice, however. The objective of this study was therefore to estimate fracture risk in relation to compliance with osteoporosis medication in actual practice...
  43. ncbi Comparing medications in a therapeutic area using an NNT model
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 7:585-94. 2004
    ....
  44. ncbi Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 7:627-35. 2004
    ..Economic evaluations typically require estimates of survival beyond the limited follow-up in clinical trials. The objective of this study was to demonstrate a data-driven approach to deriving these estimates...
  45. ncbi Meta-analysis of longitudinal studies
    K Jack Ishak
    Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
    Clin Trials 4:525-39. 2007
    ..Meta-analyses of these studies must account for correlations between effect estimates from the same study...
  46. ncbi Invasive meningococcal disease epidemiology and control measures: a framework for evaluation
    J Jaime Caro
    Caro Research Institute, Concord, MA, USA
    BMC Public Health 7:130. 2007
    ..In the absence of long-term real world data, modeling the effects of different vaccination strategies is required. Discrete event simulation provides a flexible platform with which to conduct such evaluations...
  47. ncbi The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: a qualitative review of the literature
    Krista F Huybrechts
    Caro Research Institute, 336 Baker Avenue, Concord, MA 01742, USA
    Curr Med Res Opin 23:1627-36. 2007
    ..Thus, we critically reviewed the evidence supporting the prognostic value of two frequently-used measures, the Barthel Index (BI) and modified Rankin Scale (mRS) for long-term outcomes...
  48. ncbi Modelling the economic and health consequences of cardiac resynchronization therapy in the UK
    J Jaime Caro
    Caro Research Institute, Concord, MA, USA
    Curr Med Res Opin 22:1171-9. 2006
    ..Sensitivity analyses revealed that this outcome was most sensitive to time horizon and cost of implantation. CONCLUSION: Based on these 5-year analyses, CRT is expected to yield substantial health benefits at a reasonable cost...
  49. ncbi An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation
    J Jaime Caro
    Caro Research, Concord, Massachusetts, USA
    Am J Manag Care 10:S451-58; discussion S458-61. 2004
    ....
  50. ncbi Lung cancer screening: will the controversy extend to its cost-effectiveness?
    Wendy S Klittich
    Caro Research Institute, Concord, Massachusetts, USA
    Am J Respir Med 1:393-401. 2002
    ..The publications reviewed do provide preliminary support for the economic efficiency of screening for lung cancer...
  51. ncbi Optimizing oral anticoagulation in managed care
    J Jaime Caro
    Caro Research, Concord, Massachusetts, USA
    Am J Manag Care 10:S474-7. 2004
  52. ncbi Regarding probabilistic analysis and computationally expensive models: necessary and required?
    J Jaime Caro
    Value Health 10:317-8; author reply 319. 2007
  53. ncbi QALYs: are they helpful to decision makers?
    Maurice McGregor
    Technology Assessment Unit, McGill University Health Centre, Montreal, Quebec, Canada
    Pharmacoeconomics 24:947-52. 2006
    ....
  54. ncbi Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations
    Denis Getsios
    Caro Research Institute, Halifax, Nova Scotia, Canada
    Pharmacoeconomics 23:995-1006. 2005
    ..A more definitive pharmacoeconomic comparison of oxybutynin and tolterodine formulations, incorporating all available clinical data, and other treatment options would help direct treatment...
  55. ncbi Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder
    Denis Getsios
    Caro Research Institute, Hammonds Plains, Nova Scotia, Canada
    Clin Ther 26:431-8. 2004
    ..CONCLUSION: The results of these analyses suggest that when priced equivalently, oxybutynin XL would reduce costs and provide better results than tolterodine IR over 1 year of treatment...
  56. ncbi An interview with J. Jaime Caro
    J Jaime Caro
    Am J Manag Care 10:S307-11. 2004
    ..Caro recently reported preliminary results from his economic analyses at the 2004 World Stroke Congress in Vancouver, BC. He spoke with an editor from AJMC about those studies...
  57. ncbi Pharmacoutilization of antihypertensive drugs: a model of analysis
    J Jaime Caro
    Curr Hypertens Rep 4:419. 2002
  58. ncbi Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia
    K Jack Ishak
    United BioSource Corporation, Montreal, Quebec, Canada
    Clin Ther 30:1251-63. 2008
    ....
  59. ncbi Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic
    J Jaime Caro
    Curr Hypertens Rep 4:418. 2002
  60. ncbi Summary: health and economic burden of pertussis
    David P Greenberg
    University of Pittsburgh School of Medicine, Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA
    Pediatr Infect Dis J 24:S55-7. 2005
  61. ncbi Potential strategies to reduce the burden of pertussis
    Kevin Forsyth
    Flinders University, Adelaide, Australia
    Pediatr Infect Dis J 24:S69-74. 2005
    ..However, certain steps can be taken now to reduce the incidence of pertussis...
  62. ncbi Instituting a routine varicella vaccination program in Canada: an economic evaluation
    Denis Getsios
    Caro Research, Montreal, Canada
    Pediatr Infect Dis J 21:542-7. 2002
    ..These findings are consistent with evaluations in other countries...
  63. ncbi Cost-effectiveness of cardiac resynchronization therapy
    Alexandra Ward
    J Am Coll Cardiol 48:1283. 2006
  64. ncbi An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 24)
    J Jaime Caro
    Curr Hypertens Rep 4:417. 2002
  65. ncbi Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension
    J Jaime Caro
    Curr Hypertens Rep 4:417-8. 2002
  66. ncbi Ignoring study design heterogeneity in meta-analyses
    J Jaime Caro
    Arch Intern Med 166:2046; author reply 2046-7. 2006
  67. ncbi The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism
    Joseph Jackson
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA
    Int J Dermatol 46:976-81. 2007
    ..46 to 1.62. Eflornithine is an effective treatment for unwanted facial hair in women, as reported by the patients. ESTEEM addresses the specific concerns of women with hirsutism...
  68. ncbi Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care
    Jack Ansell
    Department of Medicine, Boston University, Boston, MA 02118, USA
    Am J Med Qual 22:327-33. 2007
    ..Anticoagulation quality and record documentation were retrospectively assessed in patients with chronic nonvalvular atrial fibrillation (CNVAF) managed in a routine care setting...
  69. ncbi Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data
    Michael T Halpern
    Hypertension 47:1039-48. 2006